COVID-19, an emerging coronavirus infection : advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics
The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 16(2020), 6 vom: 02. Juni, Seite 1232-1238 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dhama, Kuldeep [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 14.07.2020 Date Revised 28.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2020.1735227 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307734501 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307734501 | ||
| 003 | DE-627 | ||
| 005 | 20231226201236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2020.1735227 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1025.xml |
| 035 | |a (DE-627)NLM307734501 | ||
| 035 | |a (NLM)32186952 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dhama, Kuldeep |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19, an emerging coronavirus infection |b advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2020 | ||
| 500 | |a Date Revised 28.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Emerging coronavirus | |
| 650 | 4 | |a drugs | |
| 650 | 4 | |a therapeutics | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Sharun, Khan |e verfasserin |4 aut | |
| 700 | 1 | |a Tiwari, Ruchi |e verfasserin |4 aut | |
| 700 | 1 | |a Dadar, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Malik, Yashpal Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Karam Pal |e verfasserin |4 aut | |
| 700 | 1 | |a Chaicumpa, Wanpen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 16(2020), 6 vom: 02. Juni, Seite 1232-1238 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2020 |g number:6 |g day:02 |g month:06 |g pages:1232-1238 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2020.1735227 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2020 |e 6 |b 02 |c 06 |h 1232-1238 | ||